Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Inducible Human Photoreceptors for Research, Development and Therapy to Prevent Blindness

Project description

Stem-cell derived photoreceptors for research and development in blindness prevention

Retinal degenerative diseases and the death of photoreceptor cells are the major causes of adult visual impairment and blindness. The team of the EU-funded iPhotoreceptors project previously developed an innovative method to differentiate human induced pluripotent stem cells into photoreceptor precursor cells using overexpression of specific transcription factors. This technology allows the fast and unlimited production of photoreceptors essential for research, photoreceptor replacement therapies and drug screenings. The current project aims to finalise the remaining development steps, define the final products, such as photoreceptor differentiation kits and cryopreserved photoreceptors, and work towards the discovery of new drugs for the treatment of retinal degeneration.

Objective

One of the major causes of adult visual impairment and blindness in industrialized countries is the progressive dysfunction and death of photoreceptor cells (PR) as a result of retinal degenerative diseases. Current treatment options are still insufficient to counteract these forms of blindness. The development of many drugs and therapies fail in preclinical stages because the used animal models are suboptimal for translating results from the bench to the bedside. Especially, for testing the transplantation of human PRs, which is currently extensively explored as a treatment option for late stages of retinal degeneration, the biggest bottleneck is the lack of PR material in sufficient quantity and quality. Within the ERC Starting Grant ProNeurons, my team and I have developed a disruptive technology to differentiate human induced pluripotent stem cells (hiPSCs) to PR precursor cells by overexpressing three transcription factors yielding in up to 60% in only 10 days. Our technology allows fast, efficient and unlimited production of PRs essential as testbeds for drug screenings, for further disease research and for photoreceptor replacement therapies. Within the PoC actions, we strive for bringing the induced PRs closer to the market. We will finalize the last product development steps and FTO reviews to define the final products such as PR differentiation kits and/or cryopreserved PRs for research, development and therapy. We will identify and approach industrial exploitation partners for out-licensing or further funding. The final goal of commercializing the induced PRs is to aid the development of new drugs to treat retinal degenerative diseases.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

ERC-POC - Proof of Concept Grant

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2020-PoC

See all projects funded under this call

Host institution

UNIVERSITATSKLINIKUM BONN
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 130 644,65
Address
VENUSBERG-CAMPUS 1
53127 BONN
Germany

See on map

Region
Nordrhein-Westfalen Köln Bonn, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Beneficiaries (2)

My booklet 0 0